CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital

D. Boral Capital began coverage on shares of CERo Therapeutics (NASDAQ:CERO) in a report released on Tuesday,Benzinga reports. The firm issued a buy rating and a $11.00 price objective on the stock.

CERo Therapeutics Stock Performance

Shares of CERO opened at $0.76 on Tuesday. CERo Therapeutics has a 1 year low of $0.53 and a 1 year high of $171.00. The stock’s fifty day moving average price is $1.10 and its two-hundred day moving average price is $6.11.

Hedge Funds Weigh In On CERo Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Avantax Planning Partners Inc. boosted its holdings in CERo Therapeutics by 89.9% in the 4th quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock worth $155,000 after buying an additional 1,224,021 shares during the period. ARCH Venture Management LLC lifted its position in shares of CERo Therapeutics by 550.4% during the fourth quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock worth $564,000 after acquiring an additional 7,949,265 shares in the last quarter. Finally, Parallel Advisors LLC bought a new position in shares of CERo Therapeutics in the first quarter worth $161,000. Institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.